Leprosy: Pathogenesis and Immunopathology

Leprosy, or Hansen's disease, is a chronic infectious condition caused by the bacterium Mycobacterium leprae. While global prevalence has declined significantly due to multidrug therapy (MDT), the disease remains a persistent public health challenge in several endemic regions. The pathogen is unique for its extreme predilection for the skin and peripheral nerves, specifically infecting Schwann cells, which leads to nerve damage and subsequent physical disabilities.

The clinical manifestation of leprosy is highly variable and depends on the host's immune response to the bacteria. The disease exists on a spectrum ranging from tuberculoid leprosy (characterized by a strong Th1-mediated immune response and low bacterial load) to lepromatous leprosy (characterized by a Th2-predominant response and high bacterial load). Genetic factors, such as polymorphisms in genes like PARK2, PACRG, and various cytokine receptors, play a significant role in determining an individual's susceptibility and the specific clinical form the disease takes.

A critical aspect of leprosy management is the occurrence of acute inflammatory episodes known as leprosy reactions. These reactions, classified as Type I (reversal reactions) and Type II (erythema nodosum leprosum), are the primary drivers of nerve damage and irreversible deformities. Type I reactions involve a shift toward a Th1-mediated inflammatory state, while Type II reactions are associated with immune complex deposition and systemic inflammation. Understanding these immunopathological pathways is essential for managing the morbidity associated with the disease, even after the bacterial infection itself has been treated.